Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi under a global ... discussed or referenced in this press release, on any of the foregoing; the likelihood, timing, and scope of possible ...

In addition to the currently approved indications, Regeneron and Sanofi are studying dupilumab in a broad ... All trademarks mentioned in this press release are the property of the Sanofi group ...

In addition to the currently approved indications, Sanofi and Regeneron are studying dupilumab in a broad range of diseases driven by type-2 inflammation or other allergic processes in phase 3 ...

1 Dupilumab is being jointly developed by Regeneron and Sanofi ... in this press release, on any of the foregoing; the likelihood, timing, and scope of possible regulatory approval and commercial ...

To date, dupilumab has been assessed across more than 60 clinical studies involving more than 10,000 patients with various chronic diseases driven in part by type-2 inflammation. In addition to the ...

| Mar. 28, 2025 14:00 ...